Extra-Nodal, Nasal, Natural Killer T-Cell Lymphoma Treated With a Checkpoint Inhibitor: A Case Report of a Sustained Complete Response.
abscopal effect
enktl
immune checkpoint inhibitor
immune therapy
pd-1 inhibitor
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
23 Apr 2021
23 Apr 2021
Historique:
entrez:
28
5
2021
pubmed:
29
5
2021
medline:
29
5
2021
Statut:
epublish
Résumé
Extra-nodal natural killer T-cell lymphoma (ENKTL) is a rare and aggressive hematologic malignancy found in the nasal cavity and adjacent locations in 80% of cases, accounting for approximately 10% of non-Hodgkin lymphoma (NHL) and 0.4% of all cancers. Prognosis is typically poor and depends on stage, location, age, and tumor markers for targeted therapy, which is reserved for relapsed/refractory ENKTL. Of those, advanced clinical stage, higher Prognostic Index (PI), nodal involvement, Ki-67 expression, large cells, local tumor invasiveness, and circulating Epstein-Barr virus (EBV)-DNA levels are predictive of worse survival. Here, we present a rare case of a patient in remission 30 months after diagnosis of ENKTL following a sustained complete response to pembrolizumab, an immune checkpoint inhibitor targeting the programmed death-1 (PD-1) receptor.
Identifiants
pubmed: 34046285
doi: 10.7759/cureus.14654
pmc: PMC8141688
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e14654Informations de copyright
Copyright © 2021, Diab et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Curr Hematol Malig Rep. 2016 Dec;11(6):514-527
pubmed: 27778143
Front Pediatr. 2019 Apr 16;7:141
pubmed: 31041299
Blood. 2015 Sep 17;126(12):1424-32; quiz 1517
pubmed: 26109206
Am J Transl Res. 2020 Nov 15;12(11):7034-7047
pubmed: 33312349
J Hematol Oncol. 2019 Mar 15;12(1):28
pubmed: 30876435
Blood. 2017 Apr 27;129(17):2437-2442
pubmed: 28188133
Blood. 2012 Oct 11;120(15):2973-80
pubmed: 22919026
Ann Hematol. 2016 Apr;95(5):847-9
pubmed: 26931114
Leuk Lymphoma. 2009 Nov;50(11):1773-84
pubmed: 19883307
J Clin Oncol. 2016 Mar 20;34(9):963-71
pubmed: 26962200
Leuk Lymphoma. 2016 Jul;57(7):1600-6
pubmed: 26726970
N Engl J Med. 2016 Oct 13;375(15):1501-1502
pubmed: 27732828
Cancer Treat Rev. 2015 Jun;41(6):503-10
pubmed: 25872878
J Hematol Oncol. 2017 Apr 14;10(1):85
pubmed: 28410601
Mol Clin Oncol. 2017 Oct;7(4):525-528
pubmed: 28855986
J Clin Oncol. 2008 Sep 1;26(25):4124-30
pubmed: 18626005
Biochim Biophys Acta. 2016 Jan;1865(1):58-71
pubmed: 26432723
Front Oncol. 2018 Apr 30;8:139
pubmed: 29761078
Oncotarget. 2016 Sep 6;7(36):58396-58404
pubmed: 27517317